AU2003236734A1 - Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles - Google Patents

Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles Download PDF

Info

Publication number
AU2003236734A1
AU2003236734A1 AU2003236734A AU2003236734A AU2003236734A1 AU 2003236734 A1 AU2003236734 A1 AU 2003236734A1 AU 2003236734 A AU2003236734 A AU 2003236734A AU 2003236734 A AU2003236734 A AU 2003236734A AU 2003236734 A1 AU2003236734 A1 AU 2003236734A1
Authority
AU
Australia
Prior art keywords
bleb
meningococcal
strain
bactericidal activity
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003236734A
Other languages
English (en)
Inventor
Ramon Faustino Barbera Morales
Pierre Michel Desmons
Francisco Jesus Dominguez Alvarez
Jan Poolman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
INSTITUTO FINLAY
Original Assignee
GlaxoSmithKline Biologicals SA
INST FINLAY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA, INST FINLAY filed Critical GlaxoSmithKline Biologicals SA
Publication of AU2003236734A1 publication Critical patent/AU2003236734A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003236734A 2002-06-13 2003-06-10 Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles Abandoned AU2003236734A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0213622.4A GB0213622D0 (en) 2002-06-13 2002-06-13 Vaccine Corporation
GB0213622.4 2002-06-13
PCT/EP2003/006094 WO2003105890A2 (en) 2002-06-13 2003-06-10 Vaccine composition

Publications (1)

Publication Number Publication Date
AU2003236734A1 true AU2003236734A1 (en) 2003-12-31

Family

ID=9938532

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003236734A Abandoned AU2003236734A1 (en) 2002-06-13 2003-06-10 Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles

Country Status (20)

Country Link
US (1) US20060110412A1 (cg-RX-API-DMAC7.html)
EP (1) EP1565211A2 (cg-RX-API-DMAC7.html)
JP (1) JP2005531614A (cg-RX-API-DMAC7.html)
KR (1) KR20050049431A (cg-RX-API-DMAC7.html)
CN (1) CN100387298C (cg-RX-API-DMAC7.html)
AR (1) AR040204A1 (cg-RX-API-DMAC7.html)
AU (1) AU2003236734A1 (cg-RX-API-DMAC7.html)
BR (1) BR0311777A (cg-RX-API-DMAC7.html)
CA (1) CA2488782A1 (cg-RX-API-DMAC7.html)
CL (1) CL2003001192A1 (cg-RX-API-DMAC7.html)
CU (1) CU23552A1 (cg-RX-API-DMAC7.html)
GB (1) GB0213622D0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04012568A (cg-RX-API-DMAC7.html)
NO (1) NO20050132L (cg-RX-API-DMAC7.html)
NZ (1) NZ560766A (cg-RX-API-DMAC7.html)
PE (1) PE20040562A1 (cg-RX-API-DMAC7.html)
RU (1) RU2005100509A (cg-RX-API-DMAC7.html)
UY (1) UY27843A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003105890A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200409547B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
JP5792920B2 (ja) * 2005-12-22 2015-10-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
SI2097102T1 (sl) 2006-09-07 2012-09-28 Glaxosmithkline Biolog Sa Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus
HRP20120433T1 (en) 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
US20090124573A1 (en) 2007-11-09 2009-05-14 Sarkis Mazmanian Immunomodulating compounds and related compositions and methods
CN101952728B (zh) * 2008-02-01 2016-05-11 圣诺菲·帕斯图尔有限公司 用于诊断肺炎链球菌的试验
SI2268618T1 (sl) 2008-03-03 2015-09-30 Novartis Ag Spojine in sestavki kot modulatorji aktivnosti TLR
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
EP2486940B1 (en) * 2009-10-08 2017-10-04 Aeon Medix Inc. Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
JP5814933B2 (ja) 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
KR20120107121A (ko) * 2009-12-22 2012-09-28 사노피 파스퇴르 리미티드 면역원성 조성물
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
HUE040658T2 (hu) * 2010-04-07 2019-03-28 California Inst Of Techn Vivõanyag vegyület mukózus membránhoz juttatásához és kapcsolódó készítmények, eljárások és rendszerek
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
ES2847923T3 (es) 2012-06-14 2021-08-04 Glaxosmithkline Biologicals Sa Vacunas contra el meningococo del serogrupo X
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
CN116670157A (zh) * 2020-10-23 2023-08-29 Omvax公司 用于抗淋病奈瑟球菌的疫苗接种的组合物和方法
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510169A (ja) * 1997-07-17 2001-07-31 ノース アメリカン ワクチン, インコーポレイテッド B型髄膜炎菌性ポーリンおよびH.influenzae多糖体を含む免疫原性結合体
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
MXPA03000822A (es) * 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.

Also Published As

Publication number Publication date
UY27843A1 (es) 2003-12-31
CA2488782A1 (en) 2003-12-24
BR0311777A (pt) 2005-03-29
MXPA04012568A (es) 2005-09-21
WO2003105890A2 (en) 2003-12-24
KR20050049431A (ko) 2005-05-25
PE20040562A1 (es) 2004-10-19
RU2005100509A (ru) 2006-06-10
CN100387298C (zh) 2008-05-14
EP1565211A2 (en) 2005-08-24
CU23552A1 (es) 2010-07-20
NO20050132L (no) 2005-02-11
JP2005531614A (ja) 2005-10-20
US20060110412A1 (en) 2006-05-25
AR040204A1 (es) 2005-03-16
ZA200409547B (en) 2006-07-26
NO20050132D0 (no) 2005-01-11
CL2003001192A1 (es) 2005-01-07
GB0213622D0 (en) 2002-07-24
CN1668329A (zh) 2005-09-14
NZ560766A (en) 2009-09-25
WO2003105890A3 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
US20060110412A1 (en) Vaccine composition
TWI360424B (en) Vaccine
JP5275983B2 (ja) ワクチン
US20170209562A1 (en) Immunogenic composition
CZ2002403A3 (cs) Vakcína
EP1572729B1 (en) Mutant frpb protein and refolding method

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted